Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.41 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | BID | P55957 | 3/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.37 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.37 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.37 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.37 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3425449 | 0.78 | LIPG (0.41) | NR1H2NR1H3CYSLTR2CYSLTR1LIPG | |
| SCHEMBL6760397 | 0.77 | LIPG (0.44) | NR1H2NR1H3CYSLTR2CYSLTR1LIPG | |
| SCHEMBL1797128 | 0.77 | LIPG (0.44) | NR1H2NR1H3CYSLTR2CYSLTR1LIPG | |
| SCHEMBL6759465 | 0.77 | LIPG (0.44) | NR1H2NR1H3CYSLTR2CYSLTR1LIPG | |
| SCHEMBL235557 | 0.77 | LIPG (0.44) | NR1H2NR1H3CYSLTR2CYSLTR1LIPG | |
| SCHEMBL8752773 | 0.77 | LIPG (0.47) | NR1H2NR1H3CYSLTR2CYSLTR1LIPG | |
| SCHEMBL6758783 | 0.77 | LIPG (0.44) | NR1H2NR1H3CYSLTR2CYSLTR1LIPG | |
| SCHEMBL167383 | 0.77 | LIPG (0.44) | NR1H2NR1H3CYSLTR2CYSLTR1LIPG | |
| SCHEMBL18242278 | 0.77 | BCHE (0.41) | NR1H2NR1H3CYSLTR2CYSLTR1LIPG | |
| SCHEMBL5176665 | 0.75 | ACHE (0.46) | NR1H2NR1H3CYSLTR2CYSLTR1LIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154008-A1 | Aryl fused substituted 4-oxy-pyridines | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-07-14 | — | — | US | claimed |
| US-20020035121-A1 | Aryl fused substituted 4-oxy-pyridines | CAI GUOLIN (US) | 2002-03-21 | — | — | US | claimed |
| WO-2002000623-A2 | ARYL FUSED SUBSTITUTED 4-OXY-PYRIDINES | NEUROGEN CORPORATION (US) | 2002-01-03 | — | — | WO | claimed |
| US-7371752-B2 | Aryl fused substituted 4-oxy-pyridines | NEUROGEN CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| US-20050154008-A1 | Aryl fused substituted 4-oxy-pyridines | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-07-14 | — | — | US | disclosed |
| US-6828329-B2 | Agonists, antagonists for gamma-aminobutyric acid brain receptors useful in diagnosis and treatment of anxiety depressionm, down syndrome, sleep and seizure disorders | NEUROGEN CORPORATION | 2004-12-07 | — | — | US | disclosed |
| US-20020035121-A1 | Aryl fused substituted 4-oxy-pyridines | CAI GUOLIN (US) | 2002-03-21 | — | — | US | disclosed |
| WO-2002000623-A2 | ARYL FUSED SUBSTITUTED 4-OXY-PYRIDINES | NEUROGEN CORPORATION (US) | 2002-01-03 | — | — | WO | disclosed |
| US-5206360-A | Bactericides | BRISTOL-MYERS SQUIBB COMPANY (US) | 1993-04-27 | — | — | US | disclosed |
| US-5169843-A | Bactericides | BRISTOL-MYERS SQUIBB COMPANY (US) | 1992-12-08 | — | — | US | disclosed |
| EP-0484030-A2 | Antibiotic C-3 cyclobutenedione substituted (1-carba)cephalosporin compounds, compositions, and methods of use thereof | Bristol-Myers Squibb Company (US) | 1992-05-06 | — | — | EP | disclosed |
| US-5106842-A | Bactericides | BRISTOL-MYERS SQUIBB CO. (US) | 1992-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154008-A1 | Aryl fused substituted 4-oxy-pyridines | CHRNA7, CHRNA4, GABRA6 | NR1H2 155/4885NR1H3 160/4885CYSLTR2 1873/4885 |
| US-20020035121-A1 | Aryl fused substituted 4-oxy-pyridines | GABRA4, GABRA6, GABRG2 | NR1H2 200/4885NR1H3 209/4885CYSLTR2 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.